Amato MP, PortaccioE, Goretti B et al. Cognitive impairment in early stages of multiple sclerosis. Neurol Sci 2010; 31(S2): 211-214.

(1)

BIBLIOGRAFIA

Amato MP, Bartolozzi ML, Zipoli V et al. Neocortical volume decrease in relapsing- remitting MS patients with mild cognitive impairment. Neurology 2004; 63: 89-93.

Amato MP, Hakiki B, Goretti B et al. Association of MRI metrics and cognitive impairment in radiologically isolated syndromes. Neurology 2012; 78: 309-314.

Amato MP, Portaccio E, Goretti B et al. The Rao’s Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population. Mult Scler 2006; 12: 787–793.

Amato MP, PortaccioE, Goretti B et al. Cognitive impairment in early stages of multiple sclerosis. Neurol Sci 2010; 31(S2): 211-214.

Amato MP, Portaccio E, Zipoli V. Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies. J Neurol Sci 2006; 245: 41-46.

Appollonio M, Leone V, Isella et al. The Frontal Assessment Battery (FAB):

normative values in an Italian population sample. Neurol Sci 2005; 26:108–116.

Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964;192:540-42.

Bakshi R, Shaikh ZA, Miletich RS et al. Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler 2000;6(3):181-5.

Barak Y, Achiron A. Effect of interferon beta-1b on cognitive functions in multiple sclerosis. Eur Neurol 2002; 47: 11-14.

Bates D. Natalizumab Re-defining efficacy in Mutiple Sclerosis: data from clinical trials to post-marketing experience. Eur Neur Rev 2009; 4(2):1-7.

Beck AT, Ward CH, Mendelson M et al. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4:561-71.

Belacchi C, Scalisi TC, Cannoni E et al. Coloured progressive Matrices CPM.

Standardizzazione italiana., Firenze 2008.

Belachew S, Phan-Ba R, Bartholomé E et al. Natalizumab induces a rapid improvment of disability status and ambulation after failure of preevious therapy in relapsing- remitting multiple sclerosis. Eur J Neurology 2010; 18(2): 240-245.

Benedict RH, Cookfair D, Gavett R et al. Validity of the minimal assessment of cognitive function in multiple sclerosis. J Int Neuropsychol Soc 2006; 12: 549-558.

Benedict RH, Munschauer FE, Linn R et al. Screening for multiple sclerosis cognitive

impairment using a self-administered 15-item questionnaire. Mult Scler 2003; 9:95-

101.

(2)

Berrios GE, Quemada JI, Andre G. Ombredane and the psychiatry of multiple sclerosis: a conceptual and statistical history. Compr Psychiatry 1990; 31(5): 438-446.

Blinkenberg M, Rune K, Jensen CV et al. Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS. Neurology 2000; 54: 558-564.

Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67(2):206-7.

Boster A, Edan G, Frohman E et al., Intense immunosppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurology 2008; 7(2): 173-183.

Caffarra P, Vezzadini G, Dieci F, Zonato F, Venneri A. A shortened version of the Stroop test: normative data in Italian population. Nuova Rivista di Neurologia 2002;

12: 111-115.

Calabrese P. Neuropsychology of multiple sclerosis: an overview. J Neurol 2006; 253:

10-15.

Carlesimo GA, Buccione I, Fadda L et al. Standardizzazione di due test di memoria per uso clinico: breve racconto e figura di Rey. Nuova rivista di Neurologia (eds) 2002; vol 12, n.1.

Carlesimo, GA, Caltagirone C, Gainotti G. The Mental Deterioration Battery:

normative data, diagnostic reliability and qualitative analyses of cognitive impairment.

The Group for the Standardization of the Mental Deterioration Battery. Eur Neurol 1996, 36(6): 378-84.

Catalan M, De Michiel A, Bratina A et al. Treatment of fatigue in multiple sclerosis patients: a neurocognitive approach. Rehabil Res Pract 2011; 670537 Epub.

Charcot JM. Histologie de la sclerose en claque. Gaz Hospital (Paris) 1848; 41: 554- 566.

Charil A, Filippi M. Inflammatory demyelination and neurodegeneration in early multiple sclerosis. J Neurol Sciences 2007; 259: 7-15.

Chaudhuri A. Fatigue in neurological disorders. Lancet 2004; 365: 978-988.

Chiaravallotti N, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurology 2008, Review; 7: 1139-1151.

Clifford DB, DeLuca A, Simpson DM et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurology 2010; 9:438-446.

Comi G, Rovaris L, Falautano M et al. A multiparametric MRI study of frontal lobe

dementia in multiple sclerosis. J Neurol Sci 1999; 171: 135-144.

(3)

Compston A et al. (eds). McAlpine’s Multiple Sclerosis, 4

^th

edition. Churchill Linvingston-Elsevier, 2006.

Coo H, Hopman WM, Edgar CM et al., The paced auditory serial addition test (PASAT): to what extent is it performed as instructed and is it associated with disease course? Mult Scler 2005; 11: 85-89.

Correale J, Peirano I, Romano L. Benign multiple sclerosis: a new definition of this entity is needed. Mult Scler 2012;18(2): 210-8. Epub 2011 Aug 24.

Dalos NP, Rabins PV, Brooks BR et al. Disease activity and emotional state in multiple sclerosis. Ann of Neurol 1983; 13: 573-577.

De Luca GC, Williams K, Evangelou N et al. The contribution of demyelination to axonal loss in multiple sclerosis. Brain 2006; 129: 1507-1516.

DeLuca J, Chelune GJ, Tulsky DS et al. Is speed of processing or working memory the primary information processing deficit in multiple sclerosis? J Clin Exp Neuropsychol 2004; 26: 550-562.

De Stefano N, Battaglini M, Stromillo ML, Zipoli V, Bartolozzi ML, Guidi L, Siracusa G et al. Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. Brain 2006; 129(8):

2008-2016.

De Stefano N, Stromillo ML, Rossi F et al. Improving the charaterization of radiologically isolated syndrome suggestive of multiple sclerosis. PlosOne 2011;

6(4):1-9.

Dubois B, Slachevsky A, Litvan I et al. The FAB: a frontal assessment battery at bedside. Neurology 2000; 55: 1621-1626.

Dutta R, McDonough J, Yin X et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 2006; 59:478-489.

EMA/430923/2010. Patient Health Protection. Assessment report for TYSABRI, International Non-proprietary Name: natalizumab. Procedure No.

EMA/H/C/000603/A20/0029. Documento EMA/H/C/000603/A20/0029;10 May 2010.

Documento EPAR, scaricato da

//www.emea.europa.eu/humandocs/Humans/EPAR/tysabri/tysabri.htm (ultimo accesso Maggio 2011).

Feinstein A. Multiple Sclerosis and depression. Mult Scler 2011; 17: 1276-1281.

Fernández O, Oreja-Guevara C, Arroyo R, et al. Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study. J Neurol. 2012 Jan 31.

Filippi M, Bozzali M, Rovaris M et al. Evidence for widespread axonal damage at the

earliest clinical stage clinical stage of multiple sclerosis. Brain 2003; 126: 433-437.

(4)

Filippi M, Rocca MA, Barkhof F et al. for the Attendees of the Correlation between Pathological MRI findings in MS workshop. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurology 2012 Review; 11(4): 349-360.

Filippi M and Rocca MA. MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system. J of Neurology 2005; 252(5): 16-24.

Filippi M, Rocca MA, Benedict RH et al. The contribution of MRI in assessing cognitive impairment in multiple sclerosis. Neurology 2010; 75(23): 2121-2128.

Filippi M, Tortorella C, Rovaris M et al., Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000;

68: 157-176.

Fisher JS. Cognitive impairment in multiple sclerosis. In: Cook SD ed. Handbook of multiple sclerosis. New York, USA: Marcel Dekker 2001; pp233-256.

Fisher JS, Rudick RA, Cutter GR and Reingold SC. The Mulitple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment. Mult Scler 1999; 5: 244-250.

Fleuren JF, Voerman GE, Erren-Wolters CV, Snoek et al. Stop using the Ashworth Scale for the assessment of spasticity. J Neurol Neurosurg Psychiatr. 2010;81(1):46- 52.

Forn C, Belenguer A, Parcet-Ibars MA et al. Information-processing speed is the primari deficit underlying the poor performance of multiple sclerosis patients in Paced Auditory Serial Additino Test (PASAT). J Clin Exp Neuropsychol 2008; 30: 789-796.

Galetta SL, Markowitz C, Lee AG. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review. Arch Intern Med 2002; 162(19):

2161-2169.

Galetta SL, Markowitz C. US FDA-approved disease-modyfing treatments for multiple sclerosis: review of effect profiles. CNS Drugs 2005; 19(3): 239-52.

Giorgio A, De Stefano N. Cognition in multiple sclerosis: relevance of lesions, brain atrophy and proton MR spettroscopi. Neurol Sci 2010; 31(S2): 245-248.

Giovagnoli AR, Del Pesce M, Mascheroni S et al. Trail making test: normative values from 287 normal adult controls. Ital J Neurol Sci. 1996; 17(4):305-9.

Giuliani F, Goodyer CG, Antel JP et al. Vulnerability of human neurons to T-cell mediated cytotoxicity. J Immunol 2003; 171: 368-379.

Goebels N, Becher B. Therapeutic antibodies in multiple sclerosis. Neurodegener Disorder 2008; 5(1): 5-7.

Gold R, Jawad A, Miller DH et al., Expert Opinion: guidelines for the use of

natalizumab in multiple sclerosis patients previously treated with immunomodulating

therapies. J Neuroimmunol 2007; 187(1-2): 156-158.

(5)

Gorelik L, Lerner M, Bixler S, Crossman M, Schlain M, Simon K, Pace A, Cheung A, et al. Anti-JC Virus Antibodies: Implications for PML Risk Stratification. Ann Neurology 2010; 68: 295-303.

Goverman J. Autoimmune T cellresponses in the centralnervous system.

NatRevImmunol 2009; 9(6):393-407.

Grant I, McDonald WI, Trimble MR et al. Deficient learning and memory in early and middle phase of MS. J Neurol Neurosurg Psychiatry 1984; 47: 250-255.

Gronwall DMA. Paced auditory serial-addition task: a measure of recovery from concussion. Perceptual and Motor Skills 1977; 44: 367-373.

Haber A, LaRocca NG.eds. Minimal Record of Disability for multiple sclerosis. New York: National Mulitple Sclerosis Society 1985.

Havrdova E, Galetta S, Hutchinson M et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009; 8: 254-260.

Hobart et al. How responsive is the multiple sclerosis impact scale (MSIS-29)? A comparison with some other self report scale. J Neurol Neurosurg Psychiatry 2005;

76(11): 1539-1543.

Horga A, Tintoré M. Natalizumab para la esclerosis multiple remitente-recurrente.

Neurologia 2011; 26: 357-368.

Huijbregts SC, Kalkers NF, de Sonneville LMJ et al. Cognitive impairment and decline in different MS subtypes. J Neurol Sci 2006; 245: 187-194.

Iaffaldano P, Gemma R, Paolicelli D et al. Impact of Natalizumab on Cognitive Performances and Fatigue in Relapsing Multiple Sclerosis: A Prospective, Open- Label, Two Years Observational Study. PlosOne, 2012; 7(4): e35843.

Janardhan V, Bakshi R. Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. J Neurol Sci 2002; 205(1):51-8.

Julian LJ, Arnett PA. Relationship among anxiety, depression, and executive functioning in multiple sclerosis. Clin Neuropsychol 2009; 23: 794-804.

Kallweit U, Jelcic I, Braun N et al. Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort. Clin Neuropharmacol. 2012; 35(2): 77- 80.

Kappos L, Bates D, Hartung HP et al. Natalizumab treatment for multiple sclerosis:

recommendations for patient selection and monitoring. Lancet Neurology 2007; 6(5):

431-41.

(6)

Keyvan TM, Kavaini H. Psychometric properties of the Persian version of Chicago Multi-Scale Depression Inventory. Iran J Psychiatry 2009; 4: 137-142.

Kobelt G, Berg J, Lindgren P et al. Costs and quality of life in mulitple sclerosis in Europe: method of assessment and analysis. Eur J Health Econ 2006; (7): 45-54.

Krupp LB, LaRocca NG, Muir-Nash J et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;

46: 1121-1123.

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33(11): 1444-1452.

Landro NI, Celius EG, Sletvold H. Depressive symptoms account for deficient information processing speed but not for impaired working memory in early MS. J Neurol Sci 2004; 217: 211-216.

Lang C, Reiss C, Maurer M. Natalizumab may improve cognition and mood in multiple sclerosis. Eur Neurol 2012; 67: 162-166.

Lebrun C, Blanc F, Brassat D et al. Cognitive function in radiologically isolated syndrome. Mult Scler 2012; 16: 919-925.

Lynch SG, Parmenter BA, Denney DR. The association between cognitive impairment and physical disability in multiple sclerosis. Mult Scler 2005; 11: 469-476.

Martinelli Boneschi F, Rovaris M, Capra R et al. Mitoxantrone for multiple sclerosis.

The Cochrane Library 2004 Review; Issue 4.

Mathiesen HK, Jonsson A, Tscherning T et al. Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis. Arch Neurol 2006; 63: 533-536.

Mattioli F, Stampatori C, Bellomi F, Capra R. Natalizumab efficacy on cognitivee impairment in MS. Neurol Sci 2011; 31(S3): 321-323.

Mattioli F, Stampatori C, Capra R. The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study. Neurol Sci 2011; 32(1): 83-8.

Miller DH, Khan OA, Sheremata WA et al. A controlled trial of natalizumab for relapsing multiple sclerosis. New Eng J Med 2003 348:15–23.

Minden SL. Mood disorders in multiple sclerosis: diagnosis and treatment. J NeuroVirology 2000; 6(S2): 160-167.

Mohr DC. Association between stressful life events and exacerbation in MS: meta- analysis. BMJ 2004; 328: 731.

Morrow SA, O’Connor PW, Polman CH et al., Evaluation of the symbol digit

modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ)

(7)

in natalizumab-treated MS patients over 48 weeks. Mult Scler 2010; 16(11): 1385- 1392.

Nyenhuis DL, Rao SM, Zajecka JM et al. Mood disturbance versus other symptoms of depression in multiple sclerosis. J Int Neuropsychol 1995; 1: 291-296.

Okuda DT, Mowry EM, Beheshtian A et al. Incidental MRI anomalies suggestive of Multiple Sclerosis. The radiologically isolated syndrome. Neurology 2009; 72:800- 805.

Otte C et al. Endocrine and immune substrates of depression sympotoms and fatigue in multiple sclerosis patient with comorbid major depression. J Neurol Neurosurg Psychiatry 2011; 82:814-818.

Oturai AB, Koch-Henriksen N, Petersen PE et al. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurology 2009; 16(3): 420-423.

O¨Yaldizli and N Putzki. Natalizumab in the treatment of multiple sclerosis. Therap Adv Neurol Dis 2009 Review; 2(2): 115-128.

Parmenter BA, Zivadinov R, Kereny L et al. Validity of the Wisconsin card sorting and delis-kaplan executive function system (DKEFS) sorting tests in multiple sclerosis. J Clin Exp Neuropsychol 2007; 29:215-223.

Patti F, Amato MP, Bastianello S et al; COGIMUS study Group. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. Mult Scler 2010; 16: 68-77.

Patti F, Lanzafame S. La terapia immunosoppressiva nella sclerosi multipla. Neurol Sciences 2005; 26(S5): 85-90.

Pedemonte E, Mancardi G, Giunti D et al., Mechanisms of adaptive immune response inside the central nervous system durino inflammatory and autoimmune diseases.

Pharmacol Ther 2006; 111(3): 555-566.

Piehl F, Holmén C, Olsson HT. Swedish nataliumab multiple sclerosis suveillance study. Neurol Sci 2010; 31(S3): 289-293.

Pittin-Vouyovitch S. Fatigue in multiple sclerosis is related to disability, depression and quality of life. J Neurol Sci 2006; 243: 39-45.

Polman CH, O’Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899–910.

Polman CH, Reingold SC, Banwell B et al. Diagnostic criteria for multiple sclerosis:

2010 Revisions to the McDonald criteria. Annals of Neurology 2011; 69(2): 292-302.

Pucci E, Giuliani G, Solari A et al. Natalizumab for relapsing remitting multiple

sclerosis. Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007621.

(8)

Ransohoff RM. Natalizumab for multiple sclerosis. New England J Medicine 2007;

356(25): 2622-2629.

Ranjeva JP, Audoin B, Duong MV et al. Local tissue damage assessed with statistical mapping analysis of brain magnetization transfer ratio: relationship with functional status of patients in the earliest stage of MS. Am J Neuroradiol 2005; 26: 119-127.

Rao S, Leo GJ, Bernardin L et al. Cognitive dysfunction in multiple sclerosis.

Frequency, patterns and prediction. Neurology 1991b; 41: 685-691.

Rao S, Leo GJ, Haughton VM et al. Correlation of magnetic resonance imaging with neuropsychological testing in MS. Neurology 1989; 39: 161-166.

Raven JC, Court JH, Raven J. Manual for Raven's Progressive Matrices and Vocabulary Scales. (Section 2) Lewis, London, 1986.

Reitan RM. Relationships between measures of brain functions and general intelligence. J Clin Psychol. 1985; 41(2):245-53.

Rey G. Concepts and stereotypes. Cognition 1983;15(1-3):237-62.

Rice GPA, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005; 64(8): 1336-1342.

Rinaldi F, Calabrese M, Seppi D et al. Natalizumab prevents the accumulation of cortical lesions in relapsing remitting multiple sclerosis: a preliminary report. Neurol Sci 2011; 31(S3): 317-320.

Rovaris M, Riccitelli G, Judica E et al. Cognitive impairment and structural brain damage in benign multiple sclerosis. Neurology 2008; 71: 1521-1526.

Rudick RA, Miller D, Hass S, et al. Health-related quality of life in multiple sclerosis:

effect of natalizumab. Ann Neurol 2007; 62(4): 335-346.

Rudick AR, O’Connor PW, Polman CH et al. Assessment of JC Virus DNA in blood and urine from Natalizumab-treaed patients. Annals of Neurology 2010; 68(3): 304- 310.

Rudick RA, Stuart WH, Calabresi PA et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911–923.

Sheremata WA, Vollmer TL, Stone LA et al. Asafety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology 1999; 52(5): 1072-1074.

Siegert RJ and Abernethy DA. Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry 2005; 76: 469-475.

Smith A. Symbol Digit Modalities Test. Los Angeles, California: Western Psychol

Services, 1982.

(9)

Solari A, Motta A, Mendozzi L et al. Italian version of the Chicago multiscale depressioni inventory: translation, adaptation and testing in people with multiple sclerosis. Neurol Sci 2003; 24: 375-383.

Sorensen PS, Bertolotto A, Edan G et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012; 18(2):

143-52.

Sorensen PS, Jonsson A. The relationship between MRI and PET changes and cognitive disturbances in MS. J Neurol Sci 2006; 245:99-102.

Sperling RA, Guttman CR, Hohol MJ et al. Regional magnetic resonance imaging lesion burden and cognitive function in multiple sclerosis: a longitudinal study. Arch Neurol 2001; 58: 115-121.

Stroop, JR. Studies of interference in serial verbal reactions. J Experim Psychology 1935; 18: 643-662.

Stuve O, Bennett JL, Hemmer B et al. Pharmacological treatment of early multiple sclerosis. Drugs 2008; 68(1): 73-83.

Surridge D. An investigation into some psychiatric aspect of multiple sclerosis. Br J Psychiatry 1969; 115(524): 749-64.

Téllez N, Río J, Tintoré M et al. Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS? Mult Scler 2005;11(2):198-202.

Tubridy N, Behan PO, Capiledeo R et al. The effect of anti-alpha4 integrin antibody on brain lesion acitvity. Neurology 1999; 53: 466-472.

Ulbrich H, Eriksson EE, Lindbom L. Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol Sciences 2003; 24(12): 640-647.

Ursell MR, O’Connor PW. Natalizumab and other monoclonal antibodies. Neurol Clin 2005; 23(1): 233-246.

Vleugels L, Lafosse C, van Nunen A et al. Visuospatial impairment in multiple sclerosis patient diagnosed with neuropsychological tasks. Mult Scler 2000; 6: 241- 254.

Yousry TA, Major EO, Ryschkewitsch C et al. Evaluation of patient treated with natalizumab for progressive multifocal leukoencephalopathy. N Eng J Med 2006; 354:

924-933.

Zabad RK, Pattern SB and Metz LM. The association of depression with disease

course in multiple sclerosis. Neurology 2005; 64: 359-360.